The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-04 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The last RAF Mustang Mk I and Mustang Mk II aircraft were struck off charge in 1945. Army Co-operation Command used the Mustang's superior speed and long range to conduct low-altitude "Rhubarb" raids over continental Europe, sometimes penetrating German airspace. The V-1710 engine ran smoothly at 1,100 rpm, versus 1,600 for the Merlin, enabling long flights over water at 50 ft (15 m) altitude before approaching the enemy coastline. Over land, these flights followed a zig-zag course, turning every six minutes to foil enemy attempts at plotting an interception. During the first 18 months of Rhubarb raids, RAF Mustang Mk.Is and Mk.Ias destroyed or heavily damaged 200 locomotives, over 200 canal barges, and an unknown number of enemy aircraft parked on the ground, for a loss of eight Mustangs. At sea level, the Mustangs were able to outrun all enemy aircraft encountered. The RAF gained a significant performance enhancement at low altitude by removing or resetting the engine's manifold pressure regulator to allow overboosting, raising output as high as 1,780 horsepower at 70 in Hg. In December 1942, Allison approved only 1,570 horsepower at 60 in Hg manifold pressure for the V-1710-39. The RAF later operated 308 P-51Bs and 636 P-51Cs, which were known in RAF service as Mustang Mk IIIs; the first units converted to the type in late 1943 and early 1944. Mustang Mk III units were operational until the end of World War II, though many units had already converted to the Mustang Mk IV (P-51D) and Mk IVa (P-51K) (828 in total, comprising 282 Mk IV and 600 Mk IVa).
Properdin is a protein that in humans is encoded by the CFP (complement factor properdin) gene. Properdin and factor H are regulatory proteins in the alternative complement pathway. Properdin is an up-regulator, stabilizing the C3bBb complex, and factor H is the down-regulator, promoting proteolytic degradation of C3b. Factor H is primarily produced in the liver, whereas properdin is sourced in neutrophils, monocytes, T cells and bone marrow progenitor cell line. Properdin is plasma glycoprotein that activates the complement system of the innate immune system. It is found in plasma and primarily produced by leukocytes. This protein binds to bacterial cell walls and dying human cells to stabilize the C3 and C5-convertase enzyme complexes to form an attack complex that leads to the lysis of the cell. The complement system is made of plasma and membrane-bound proteins that go through the blood to get rid of pathogens and damaged cells. Activation of the complement system occurs via three pathways, the classical, lectin, and alternative pathways. Activation of the alternative pathway occurs in bacteria, yeast, and parasites and is stimulated by antibody-antigen complexes made of IgG or IgA. Properdin and factor H are important regulatory proteins of the alternative pathway, which is initiated by a conformational change in C3 cleaved at a single site by the serine protease C3 convertase.
== Research == Due to its high biocompatibility, bioactivity, osteoconductive and/or osteoinductive capacity, nontoxicity, nonimmunogenic properties, and noninflammatory behavior, hydroxyapatite is available and used as a bone filler and as coatings on prostheses. Designing bone scaffolds with a higher capability of promoting bone regeneration is a topical research subject. Composite 3D scaffolds for bone tissue engineering based on nano-hydroxyapatite and poly-ε-caprolactone were designed. The 3D composite scaffolds showed good cytocompatibility and osteogenic potential, which is specifically recommended in applications when faster mineralization is needed, such as osteoporosis treatment.
Sources: en.wikipedia.org
==== Actions ==== The 2C drugs act as agonists of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. They are partial agonists of the serotonin 5-HT2A receptor. Most of the 2C drugs have much lower affinity for the serotonin 5-HT1A receptor than for the serotonin 5-HT2A receptor. Most of the 2C drugs have also shown about 5- to 15-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor and about 15- to 100-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT1A receptor. The psychedelic effects of the 2C drugs are thought to be mediated specifically by activation of the serotonin 5-HT2A receptor. Unlike many other phenethylamines, 2C drugs, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2 among others, are inactive as monoamine releasing agents and reuptake inhibitors. Most of the 2C drugs are agonists of the rat and mouse trace amine-associated receptor 1 (TAAR1). However, most are inactive as agonists of the human TAAR1. The 2C drugs show very weak monoamine oxidase inhibition, including of monoamine oxidase A (MAO-A) and/or monoamine oxidase B (MAO-B).
==== Sulfur ==== The sulfur stable isotope system is based on small, mass-dependent fractionations of sulfur isotopes. These fractionations are reported relative to Canyon Diablo Troilite (V-CDT), the agreed upon standard. The ratio of the most abundant sulfur isotope, 32S, compared to rarer isotopes such as, 33S, 34S, and 36S, is used to characterize biological signatures and geological reservoirs. The fractionation of 34S (δ34S) is particularly useful since it is the most abundant of the rare isotopes. This system is less commonly used on its own and typically complements studies of carbon and nitrogen. In bioarchaeology, the sulfur system has been used to investigate paleodiets and spatial behaviors through the analysis of hair and bone collagen. Dietary proteins incorporated into living organisms tend to determine the stable isotope values of their organic tissues. Methionine and cysteine are the canonical sulfur-containing amino acids. Of the two, δ34S values of methionine are considered to better reflect isotopic compositions of dietary sulfur, since cysteine values are impacted by diet and internal cycling. While other stable isotope systems have significant trophic shifts, sulfur shows only a small shift (~0.5‰).
For example, most crustose lichens have intracellular haustoria, whereas foliose and fruticose lichens tend to have intraparietal ones. In lichens whose Trebouxia partner bears a sporopollenin-rich wall, the fungus cannot penetrate and resorts to the intraparietal strategy. The interface therefore records co-evolution, and haustorial type may flag evolutionary shifts or delimit higher taxa. Scanning-electron microscopy (SEM) and freeze-etching next exposed the outer surfaces of lichen hyphae. Honegger (1984) freeze-fractured thalli to reveal successive wall layers and surface textures. She showed that symbiotic hyphae develop characteristic coatings: Peltigera species carry dense protein rodlets, whereas genera such as Parmelia and Cladonia display patchy, maze-like mosaics. Cultured (non-symbiotic) isolates lack these coatings, confirming their symbiotic origin. Because wall textures are consistent within genera or families, they became additional diagnostic traits. Functionally, the coatings likely improve adhesion to the algal partner. Freeze-etch images also revealed matching pits or projections in the algal wall, forming an interlocking contact surface. These precise contact structures demonstrate how symbiotic integration can produce distinctive morphological characters. Together with haustorial form, these ultrastructural characters aid genus- or family-level delimitation and illuminate how often particular symbiotic mechanisms evolved—issues now revisited with molecular datasets.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.